RT Journal Article
T1 Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
A1 Bacián Martínez, Sandra
A1 Navarro Cuéllar, Carlos
A1 Navarro Vila, Carlos
A1 Palacios Weiss, Edurne
A1 Pujol Romanyá, Roser
A1 Amo Fernández de Velasco, Álvaro del
A1 Escrig de Teijeiro, Margarita
A1 Castillo Pardo de Vera, José Luis del
A1 Rodríguez Pérez, Irene
A1 Sánchez-Pérez, Arturo
A1 Zamorano León, José Javier
A1 López Farre, Antonio José
A1 García-Hidalgo Alonso, María Isabel
A1 Navarro Cuéllar, Ignacio
AB Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activation of the RANK receptor on the surface of osteoclasts, has been associated with osteonecrosis of the jaw. Primary intraosseous squamous cell carcinoma (PIOSCC) is a rare neoplasm characterised by the presence of squamous cells within the maxillary or mandibular bone without an initial clinical association with the oral mucosa. We present a case of a PIOSCC in an osteonecrosis of the jaw related to a patient who received antiresorptive treatment with denosumab outlining the clinical and histopathological features of MRONJ and PIOSCC.
PB MPDI
SN 2076-3417
YR 2021
FD 2021-08-20
LK https://hdl.handle.net/20.500.14352/4737
UL https://hdl.handle.net/20.500.14352/4737
LA eng
NO Bacián Martínez, S., Navarro Cuéllar, C., Navarro Vila, C. et al. «Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw». Applied Sciences, vol. 11, n.o 16, agosto de 2021, p. 7646. DOI.org (Crossref), https://doi.org/10.3390/app11167646.
DS Docta Complutense
RD 9 may 2025